A Safety and Efficacy Study of Tavilermide Ophthalmic Solution for the Treatment of Dry Eye

Trial Profile

A Safety and Efficacy Study of Tavilermide Ophthalmic Solution for the Treatment of Dry Eye

Completed
Phase of Trial: Phase III

Latest Information Update: 29 Mar 2017

At a glance

  • Drugs Tavilermide (Primary)
  • Indications Keratoconjunctivitis sicca
  • Focus Therapeutic Use
  • Sponsors Mimetogen Pharmaceuticals
  • Most Recent Events

    • 24 Mar 2017 Status changed from active, no longer recruiting to completed.
    • 12 Sep 2016 Planned End Date changed from 1 Jul 2016 to 1 Sep 2016.
    • 12 Sep 2016 Planned primary completion date changed from 1 Jul 2016 to 1 Sep 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top